MIBG Scintigraphy as a Tool for Selecting Patients Requiring Implantable Cardioverter Defibrillator (ICD) (MISTIC)
|ClinicalTrials.gov Identifier: NCT01185756|
Recruitment Status : Active, not recruiting
First Posted : August 20, 2010
Last Update Posted : January 11, 2018
|Condition or disease||Intervention/treatment||Phase|
|Heart Failure Sudden Death||Radiation: MIBG for diagnostic purpose||Not Applicable|
The survival benefit provided by implantable cardioverter defibrillator (ICD) for primary prevention of sudden cardiac death in heart failure compared to medical treatment alone is well established. First limited to the most severe patients, the indications have gradually been extended in accordance with the results of more recent studies. This beneficial effect in terms of public health is accompanied by an increase in health spending which threatens to grow strongly at short and medium term. However, the majority of ICDs implanted will not be solicited because of the overall low incidence of severe ventricular arrhythmias in the population meeting the implantation criteria. To optimize our resources, it is therefore important to better assess the risk of sudden death in those patients candidates for ICD implantation.
The overactivation of NEURO-humoral systems plays an important role in the progression of heart failure, and in the occurrence of ventricular arrhythmias. The iodine-123 meta-iodobenzylguanidine scintigraphy (MIBG), is a functional imaging method that can noninvasively evaluate cardiac sympathetic innervation. It has been shown that cardiac adrenergic hyperactivation estimated by MIBG scintigraphy was associated with a poor outcome, and that its value was independent and superior to other prognostic factors in heart failure. More importantly, the risk of occurrence of major cardiac events is minimal when the cardiac uptake of MIBG is high. Furthermore, plasma natriuretic peptides (particularly BNP and NT-proBNP), which are other indicators of the NEURO-hormonal activation used in the diagnosis and assessment of prognosis in heart failure, are predictive of the risk of occurrence of sudden death in the same population. In summary, the MIBG scintigraphy and NT-proBNP are two prognostic markers in heart failure related to the degree of NEURO-hormonal dysfunction, and have a good negative predictive value of mortality. Their combined use could therefore help identify patients at low risk of severe arrhythmias.These tests are not currently part of heart failure diagnosis in patients who are candidates for ICD implantation.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||330 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Can we Better Select Patients With Heart Failure for a Primary Prevention Indication of Implantable Cardioverter Defibrillator (ICD)? Evaluation of the Diagnostic Value of 123I Meta-iodobenzylguanidine (MIBG)|
|Actual Study Start Date :||September 2010|
|Actual Primary Completion Date :||March 2017|
|Estimated Study Completion Date :||January 2018|
Experimental: ICD implantation
MIBG for diagnostic purpose:
MIBG scintigraphy for diagnostic purpose
Radiation: MIBG for diagnostic purpose
All patients will undergo the diagnostic test specific to the study.
- Assessment of the cardiac MIBG uptake ratio for identification of patients at very low risk of severe ventricular arrhythmias. [ Time Frame: 1-3 months ]Description appropriate therapy delivered by the ICD, or sustained ventricular tachycardia.
- Sudden cardiac death [ Time Frame: 1-3 months ]
- Overall mortality [ Time Frame: 1-3 months ]
- Assessment of the cardiac MIBG uptake ratio for identification of patients at very low risk of severe ventricular arrhythmias. [ Time Frame: every 6 months during 3 years ]description appropriate therapy delivered by the ICD or sustained ventricular tachycardia
- sudden cardiac death [ Time Frame: every 6 months during 3 years ]
- Overall mortality [ Time Frame: every 6 months during 2 years ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01185756
|Groupe Hospitalier Bichat - Claude Bernard|
|Paris, Ile De France, France, 75018|
|Principal Investigator:||Dominique Le Guludec, MD, PhD||Assistance Publique - Hôpitaux de Paris|